- Home
- VOR vs CBIO Comparison
VOR vs CBIO Comparison
Compare VOR & CBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VOR
- CBIO
- Stock Information
- Founded
- VOR 2015
- CBIO 2003
- Country
- VOR United States
- CBIO United States
- Employees
- VOR N/A
- CBIO N/A
- Industry
- VOR Biotechnology: Pharmaceutical Preparations
- CBIO
- Sector
- VOR Health Care
- CBIO
- Exchange
- VOR Nasdaq
- CBIO Nasdaq
- Market Cap
- VOR 261.0M
- CBIO 308.0M
- IPO Year
- VOR 2021
- CBIO N/A
- Fundamental
- Price
- VOR $1.97
- CBIO $13.26
- Analyst Decision
- VOR Buy
- CBIO Strong Buy
- Analyst Count
- VOR 6
- CBIO 5
- Target Price
- VOR $3.90
- CBIO $25.60
- AVG Volume (30 Days)
- VOR 4.8M
- CBIO 92.9K
- Earning Date
- VOR 08-12-2025
- CBIO 07-31-2025
- Dividend Yield
- VOR N/A
- CBIO N/A
- EPS Growth
- VOR N/A
- CBIO N/A
- EPS
- VOR N/A
- CBIO N/A
- Revenue
- VOR N/A
- CBIO N/A
- Revenue This Year
- VOR N/A
- CBIO N/A
- Revenue Next Year
- VOR N/A
- CBIO N/A
- P/E Ratio
- VOR N/A
- CBIO N/A
- Revenue Growth
- VOR N/A
- CBIO N/A
- 52 Week Low
- VOR $0.13
- CBIO $10.83
- 52 Week High
- VOR $3.29
- CBIO $21.40
- Technical
- Relative Strength Index (RSI)
- VOR 48.04
- CBIO 44.24
- Support Level
- VOR $2.05
- CBIO $13.50
- Resistance Level
- VOR $2.11
- CBIO $14.74
- Average True Range (ATR)
- VOR 0.16
- CBIO 0.82
- MACD
- VOR -0.03
- CBIO 0.02
- Stochastic Oscillator
- VOR 5.28
- CBIO 8.88
About VOR Vor Biopharma Inc.
Vor Biopharma Inc is a clinical stage cell therapy company. It combines a novel patient engineering approach with targeted therapies to provide a solution for patients suffering from hematological malignancies. The company's products include VCAR33, Tremcel and Myelodysplastic Syndrome, Trem-cel+VCAR33 Treatment System, VADC45, CD123, CLL1, EMR2.
About CBIO Crescent Biopharma Inc. Common Stock
Crescent Biopharma Inc is a biopharmaceutical company developing novel therapeutics to treat solid tumors, led by CR-001, a proprietary anti-PD-1/anti-VEGF bispecific antibody. Crescent believes CR-001 has the potential to deliver improved clinical efficacy and safety over pembrolizumab. CR-001 is a new molecular entity designed to replicate the functional properties of ivonescimab, a cooperative bispecific anti-PD-1/anti-VEGF antibody in development by Akeso Biopharma and Summit Therapeutics that delivered improved efficacy in a head-to-head Phase 3 clinical trial versus Keytruda in non-small cell lung cancer. Crescent is advancing its second and third programs, CR-002 and CR-003, which are antibody drug conjugates (ADCs) against validated oncology targets.